• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Technical Ops Officer Abele Stefan Andreas sold $260,864 worth of shares (8,748 units at $29.82), decreasing direct ownership by 20% to 35,194 units (SEC Form 4)

    5/19/26 6:44:54 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Abele Stefan Andreas

    (Last)(First)(Middle)
    1 CRANBERRY HILL SUITE 400

    (Street)
    LEXINGTON MASSACHUSETTS 02421

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Pharvaris N.V. [ PHVS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Technical Ops Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/15/2026S8,748D$29.8199(1)35,194D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates.
    /s/ Marnus Nel, Attorney-in-Fact for Stefan Abele05/19/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $PHVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    4/9/2026$42.00Outperform
    Wolfe Research
    3/9/2026$52.00Outperform
    RBC Capital Mkts
    10/15/2025$60.00Buy
    H.C. Wainwright
    10/9/2025$27.00Underperform → Neutral
    BofA Securities
    6/11/2025$32.00Buy
    Guggenheim
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $PHVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Monges Viviane sold $292,853 worth of shares (9,667 units at $30.29), decreasing direct ownership by 64% to 5,500 units (SEC Form 4) to satisfy tax liability

    4 - Pharvaris N.V. (0001830487) (Issuer)

    5/26/26 5:53:25 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Nijdam Anna exercised 7,330 shares at a strike of $20.00 and sold $225,055 worth of shares (7,330 units at $30.70) (SEC Form 4) to satisfy withholding obligation

    4 - Pharvaris N.V. (0001830487) (Issuer)

    5/26/26 5:45:32 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO / CLO Nassif David W. sold $303,076 worth of shares (10,000 units at $30.31), decreasing direct ownership by 8% to 120,300 units (SEC Form 4) to satisfy withholding obligation

    4 - Pharvaris N.V. (0001830487) (Issuer)

    5/26/26 5:42:08 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Pharvaris N.V. with a new price target

    Wolfe Research initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $42.00

    4/9/26 8:43:44 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pharvaris N.V. with a new price target

    RBC Capital Mkts initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $52.00

    3/9/26 9:07:59 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Pharvaris N.V. with a new price target

    H.C. Wainwright initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $60.00

    10/15/25 8:31:21 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

    ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title: Oral Deucrictibant Im

    5/29/26 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

    Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksCash and cash equivalents of €247 million as of March 31, 2026; subsequent closing of $132 million underwritten offering extends cash runway into 2028 ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonis

    5/12/26 4:05:00 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

    ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ("HAE") and acquired angioedema due to C1 inhibitor deficiency ("AAE-C1INH"), today announced the closing of its previously announced underwritten offering of 4,455,863 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 581,199 ordinary shares). The gross proceeds to Pharvaris from the offering, before deducting underwriting di

    5/11/26 4:15:00 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    SEC Filings

    View All

    SEC Form 144 filed by Pharvaris N.V.

    144 - Pharvaris N.V. (0001830487) (Subject)

    5/21/26 5:27:32 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Pharvaris N.V.

    144 - Pharvaris N.V. (0001830487) (Subject)

    5/20/26 5:23:24 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.

    SCHEDULE 13G/A - Pharvaris N.V. (0001830487) (Subject)

    5/15/26 5:48:36 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Financials

    Live finance-specific insights

    View All

    Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

    Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)Well-tolerated safety profile of deucrictibant confirmedEfficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locationsPharvaris to host a conference call and webcast today at 8:00 a.m. EST ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutica

    12/3/25 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

    CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

    9/5/24 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

    Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

    12/6/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 8:42:52 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 10:27:18 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/13/24 2:14:59 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Elisabeth Björk as Board Member

    NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

    6/17/25 7:00:00 AM ET
    $PHVS
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

    ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

    11/15/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care